Jazz Pharmaceuticals Stock News

Bojan Bogdanovic said making a Utah Jazz franchise-record 11 3-pointers wasn''t all that complicated.

The Ukrainian National Federation in Montreal is working with Ukrainian government ministries to make sure the funds raised go to those who need it the most.

The Utah Jazz and the Pelicans each have won three games in a row going into their meeting Friday night in New Orleans. But while the Pelicans have rolled past their opponents by an average of 24.3 points, the Jazz have had a much more difficult time. Utah’s wins have come by five, four and […]

The U.S. District Court for the Western District of Texas dismissed a lawsuit filed by Canadian cannabis giant Canopy Growth (NASDAQ: CGC) against GW Pharmaceuticals on Feb. 25th. The lawsuit was

The U.S. District Court for the Western District of Texas dismissed a lawsuit filed by Canadian cannabis giant C…

The U.S. District Court for the Western District of Texas dismissed a lawsuit filed by Canadian cannabis giant Canopy Growth (NASDAQ: CGC ) against GW Pharmaceuticals on Feb. 25th . The lawsuit was initially filed in 2020, and since then, Britain’s GW Pharma was acquired by the biopharmaceutical company Jazz Pharmaceuticals (NASDAQ: JAZZ ). In the lawsuit, Canopy accused GW Pharma of unauthorized usage of Canopy’s intellectual property related to a CBD extraction method . Canopy said it had obtained the intellectual property with its acquisition of Germany’s C3 Cannabinoid Compound Co. in 2019 for more than $250 million . The same day the lawsuit was filed, Canopy was issued the U.S. patent. According to Canopy, GW Pharma has been relying on the extraction method in question for the production of its flagship epilepsy drug Epidolex. Canopy said that … Full story available on Benzinga.com

The Japanese carmaker has announced heavy discounts across its existing line-up in India. The offers are available throughout this month

Donovan Mitchell had 37 points and Mike Conley scored nine points in overtime to help the Utah Jazz outlast the Houston Rockets 132-127 Wednesday night.

The biotech's better-than-expected Q4 financial results are fueling a rally in its stock.

The biotech''s better-than-expected Q4 financial results are fueling a rally in its stock.

Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 3 0 0 0

Jazz Pharmaceuticals <> has recorded the biggest intraday gain since 2017 on Wednesday to reach a six-month high on the strong Q4 earnings beat reported by the…

Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) shares … Full story available on Benzinga.com

JAZZ's product revenues grow in the fourth quarter on the back of strong demand for its new drugs and drugs added with the acquisition of GW Pharmaceuticals.

The biotech's better-than-expected Q4 financial results are fueling a rally in its stock.